Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 7.8% – Should You Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s stock price traded down 7.8% during mid-day trading on Wednesday. The stock traded as low as $25.10 and last traded at $24.7830. 194,579 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 239,758 shares. The stock had previously closed at $26.89.

Analysts Set New Price Targets

FTH has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective on the stock. Guggenheim initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 16th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Down 8.5%

The firm has a market cap of $635.66 million, a price-to-earnings ratio of -0.17 and a beta of -0.29. The company has a 50-day simple moving average of $32.00.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. Research analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Institutional Trading of Sensei Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics during the 2nd quarter valued at $3,610,000. Renaissance Technologies LLC lifted its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the period. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth $4,188,000. Finally, Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at $22,758,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.